These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 22866363

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Using concordance with dosing techniques to achieve phosphate control.
    Koester LA, Rothstein M.
    Nephrol News Issues; 2013 Nov; 27(12):22, 24, 26-8 passim. PubMed ID: 24354233
    [Abstract] [Full Text] [Related]

  • 3. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.
    Fishbane S, Delmez J, Suki WN, Hariachar SK, Heaton J, Chasan-Taber S, Plone MA, Moe S.
    Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sevelamer.
    Wrong O, Harland C.
    Nephrol Dial Transplant; 2008 Jun; 23(6):2108; author reply 2101-2. PubMed ID: 18400812
    [No Abstract] [Full Text] [Related]

  • 7. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
    Runowski D, Jachimiak B, Cieślak-Puchalska A, Pacanowska B, Zimoń T.
    Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis.
    Fan S, Ross C, Mitra S, Kalra P, Heaton J, Hunter J, Plone M, Pritchard N.
    Nephrol Dial Transplant; 2009 Dec; 24(12):3794-9. PubMed ID: 19666658
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Phosphate binders in chronic kidney disease: the positions of sevelamer].
    Fomin VV, Shilov EM, Svistunov AA, Milovanov IuS.
    Ter Arkh; 2013 Dec; 85(6):96-9. PubMed ID: 23875200
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Novel dosage forms and regimens for sevelamer-based phosphate binders.
    Duggal A, Hanus M, Zhorov E, Dagher R, Plone MA, Goldberg J, Burke SK.
    J Ren Nutr; 2006 Jul; 16(3):248-52. PubMed ID: 16825030
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ.
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.